FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy
The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.
Source: pharmacytimes.com